- Home
- OVID vs IPHA Comparison
OVID vs IPHA Comparison
Compare OVID & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OVID | IPHA |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | France |
| Employees | N/A | 174 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.5M | 119.1M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | OVID | IPHA |
|---|---|---|
| Price | $2.51 | $1.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $4.20 | ★ $5.75 |
| AVG Volume (30 Days) | ★ 3.1M | 13.1K |
| Earning Date | 03-18-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,252,000.00 | N/A |
| Revenue This Year | $1,077.56 | $28.31 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1181.27 | N/A |
| 52 Week Low | $0.24 | $1.18 |
| 52 Week High | $2.72 | $2.63 |
Technical Indicators
Market Signals| Indicator | OVID | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 76.72 | 37.20 |
| Support Level | $1.31 | N/A |
| Resistance Level | N/A | $1.88 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 82.11 | 36.17 |
Price Performance
Historical ComparisonAbout OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.